MiRNA-based Lifespan extension therapy: MiRNA-138 promotes mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 5/June/2014, 7.49 am

MiRNA-based therapy for Human Cancer: MiRNA-765 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via up regulation of its target gene, 5/June/2015, 07.45 pm
June 5, 2015
Natural product-based High-Density lipoprotein therapy: Fumigaclavine C increases High-Density lipoprotein levels via up regulation of ABCA1, 5/June/2015, 7.53 am
June 5, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, L., MiRNA-based Lifespan extension therapy: MiRNA-138 promotes mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 5/June/2014, 7.49 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: It has been shown earlier that angiotensin II type I receptor (AT1R) antagonist prolongs mammalian life span. This study suggests, for the first time, that MiRNA-138, by decreasing the expression of its target gene,  it may suppress the expression of AT1R. And, thereby, it may (1) decrease blood pressure; and (2) and extend the lifespan of an individual. Thus, pharmacological formulations encompassing “MiRNA-138 activators may be used to extend the life-span of an individual.

Undisclosed information: How MiRNA-138 suppresses the expression of  angiotensin II type I receptor (AT1R)

# Research cooperation

Comments are closed.